Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Autolus Therapeutics Ltd is a biotechnology business based in the US. Autolus Therapeutics shares (AUTL) are listed on the NASDAQ and all prices are listed in US Dollars. Autolus Therapeutics employs 324 staff and has a trailing 12-month revenue of around $582,000.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $2.23 |
|---|---|
| 52-week range | $1.96 - $7.90 |
| 50-day moving average | $3.06 |
| 200-day moving average | $3.62 |
| Wall St. target price | $15.06 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.84 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.23 from 2022-09-29
| 1 week (2022-09-23) | 9.31% |
|---|---|
| 1 month (2022-09-01) | -31.17% |
| 3 months (2022-07-01) | -18.91% |
| 6 months (2022-04-01) | -47.41% |
| 1 year (2021-10-01) | -66.72% |
|---|---|
| 2 years (2020-10-01) | -80.83% |
| 3 years (2019-10-01) | 11.78 |
| 5 years (2017-09-27) | N/A |
| Revenue TTM | $582,000 |
|---|---|
| Gross profit TTM | $-132,459,000 |
| Return on assets TTM | -34.06% |
| Return on equity TTM | -62.13% |
| Profit margin | 0% |
| Book value | $2.36 |
| Market capitalisation | $185.5 million |
TTM: trailing 12 months
We're not expecting Autolus Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Autolus Therapeutics's shares have ranged in value from as little as $1.96 up to $7.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Autolus Therapeutics's is 1.2854. This would suggest that Autolus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.